Valneva approaches the goal.
The Franco-Austrian biotech announced Monday that it was starting the gradual submission of the authorization file for its anti-Covid vaccine to the British health authorities.
This process saves time for commercialization as Phase III clinical trials continue.
With the first results expected at the start of the fourth quarter, Valneva hopes to get the green light
"by the end of 2021"
.
Other studies are being carried out in parallel on the effectiveness of this vaccine in the elderly, as well as for its use as a booster.
The announcement of Valneva boosted its title which gained 4.5% on Monday, to 12.8 euros on Euronext.
Read also
Why the French nugget Valneva will deliver its first vaccines to the British
The choice of the British authorities to start this regulatory procedure is explained by the privileged links established with the country by Valneva, resulting from the merger, eight years ago, between the French Vivalis and the Austrian Intercell.
Great Britain, in fact, brought it last year a
This article is for subscribers only.
You have 67% left to discover.
To cultivate your freedom is to cultivate your curiosity.
Keep reading your article for € 1 for 2 months
I ENJOY IT
Already subscribed?
Log in
